Table 2.
Participants with CSF.
| HC | PD-NC | PD-MCI | PDD | Total PD | |
|---|---|---|---|---|---|
| Total participants | 8 | 18 | 8 | 3 | 29 |
| Participants with CSF | 8 | 10 | 5 | 3 | 18 |
| Positive AD CSF biomarkers | 0 | 1 | 2 | 2 | 5 |
| Negative AD CSF biomarkers | 8 | 9 | 3 | 1 | 13 |
| Unknown AD CSF biomarkers | 0 | 8 | 3 | 0 | 11 |
Based on an independent cohort of 21 healthy controls and 14 clinical AD participants we used a cutoff of Aβ1–42 ≤ 660 and p-tau ≥60 to determine possible dual PD/AD pathology due to positive AD CSF biomarkers.
Abbreviations: AD = Alzheimer's disease, CSF = cerebral spinal fluid, HC = Healthy Controls, PD-NC = PD with cognition in the normal range, PD-MCI = PD with mild cognitive impairment, PDD = PD with dementia.